Drug Profile
RSV MEDI deltaM2-2
Alternative Names: M2-2 RSV vaccine - AstraZeneca; Medi RSV M2-2 vaccine; Medi-RSV-delta-M2-2 vaccine; Respiratory-syncytial virus vaccine M2-2 – AstraZeneca; RSV MEDI deltaM2-2 vaccine; RSV vaccine intranasal - AstraZenecaLatest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
- Class Attenuated vaccines; DNA vaccines; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention, In adults) in USA (Intranasal, Drops)
- 01 Aug 2011 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants, children and adults) in USA (Intranasal)
- 01 Jan 2000 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal)